keyword
MENU ▼
Read by QxMD icon Read
search

Folfox

keyword
https://www.readbyqxmd.com/read/29333014/is-colorectal-cancer-in-young-40-years-different-from-those-in-the-elderly-40-years-experience-from-a-regional-care-center
#1
Rudresha A Haleshappa, Suparna Ajit Rao, Sunny Garg, C Lakshmaiah Kuntegowdanahalli, Govinda Babu Kanakasetty, Lokanatha Dasappa
Background: Colorectal cancer (CRC) is considered a disease of elderly. There has been a steady decrease in the incidence in those aged >50 years, with an alarming increase noted in adults aged <50 years. Subjects and Methods: We retrospectively analyzed 89 patients diagnosed with CRC aged <40 years between the years 2010 and 2014. Their clinical profile, treatment, and outcomes were studied. Results: The median age was 33 years with a male preponderance (56...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29315736/dosing-oxaliplatin-in-a-haemodialysis-patient-with-metastatic-rectum-cancer-monitored-by-free-platinum-concentrations
#2
I R F van Berlo-van de Laar, W J Brummelhuis, A L T Imholz, J H Schellens, A D R Huitema, F G A Jansman
WHAT IS KNOWN AND OBJECTIVE: Oxaliplatin in combination with fluorouracil and folinic acid is one of the preferred chemotherapeutic options in the treatment of metastatic rectum cancer. However, oxaliplatin is contraindicated in patients with a creatinine clearance <30 mL/min and dosing guidelines in patients on haemodialysis have not been established. CASE SUMMARY: A 77-year-old haemodialysis patient with metastatic rectum cancer was treated with FOLFOX and bevacizumab (oxaliplatin 70 mg/m2 , folinic acid 200 mg/m2 , 5-FU 340 mg/m2 bolus and 2040 mg/m2 continuous infusion during 44 hours and bevacizumab 5 mg/kg) every three weeks...
January 5, 2018: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29299827/apical-lymph-nodes-in-the-distant-metastases-and-prognosis-of-patients-with-stage-iii-colorectal-cancer-with-adequate-lymph-node-retrieval-following-folfox-adjuvant-chemotherapy
#3
Hsiang-Lin Tsai, Yi-Ting Chen, Yung-Sung Yeh, Ching-Wen Huang, Cheng-Jen Ma, Jaw-Yuan Wang
The aim of the study was to assess apical lymph nodes (APNs) for predicting distant metastases in patients with stage III colorectal cancer (CRC) curatively treated with FOLFOX adjuvant chemotherapy and adequate lymph node retrieval. We investigated the correlation between APN metastasis and clinical outcomes. This retrospective study examined 97 patients. All patients were followed until death, loss to follow-up, or May 2017. Clinicopathological variables, including the APN status, were assessed. Multivariate logistic regression model was used to identify the independent risk factors for APN and distant metastases, and Cox proportional regression model was used to evaluate the association between APN metastasis and oncologic outcomes...
January 3, 2018: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29299370/safety-of-selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-combined-with-systemic-anticancer-agents-expert-consensus
#4
REVIEW
Andrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, John Marshall, Harpreet Wasan, Marwan Fakih, Peter Gibbs, Alexander Knuth, Bruno Sangro, Michael C Soulen, Gianfranco Pittari, Ricky A Sharma
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors. Eligible patients have usually been exposed to a variety of systemic anticancer therapies, including cytotoxic agents, targeted biologics, immunotherapy and peptide receptor radionuclide therapy (PRRT). All these treatments have potential interactions with SIRT; however, robust evidence on the safety of these potential combinations is lacking...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29299351/a-phase-2-trial-of-personalized-cytotoxic-therapy-based-on-tumor-immunohistochemistry-in-previously-treated-metastatic-pancreatic-cancer-patients
#5
Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, N V Rajeshkumar, Gayle Jameson, Meraj Aziz, Antje Hoering, Vanessa Bolejack, Anirban Maitra, Monica Fulk, Edward C Stites, William S Hlavacek, Zoran Gatalica, Joanne Xiu, Manuel Hidalgo, Daniel D Von Hoff, Michael T Barrett
Background: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies. Methods: Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29281948/a-patient-with-oxaliplatin-immune-induced-syndrome-oiis-who-also-developed-leucovorin-and-palonosetron-associated-thrombocytopenia
#6
S A Curtis, B R Curtis, A I Lee, J E Hendrickson, J Lacy, N A Podoltsev
OBJECTIVES: We report a case of an 83 year old man who developed oxaliplatin immune-induced syndrome (OIIS) after his 19th cycle of FOLFOX (5FU, leucovorin, oxaliplatin). When oxaliplatin was omitted from his next cycle of chemotherapy he continues to show signs of drug-induced immune thrombocytopenia (DITP) and was found to have drug-dependent, platelet-reactive antibodies (DDPA) to leucovorin and palonosetron as well as oxaliplatin. METHODS: The patient was admitted for monitoring but required no transfusions and thrombocytopenia resolved without treatment during his first admission...
December 28, 2017: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/29246011/network-meta-analysis-of-the-efficacy-of-first-line-chemotherapy-regimens-in-patients-with-advanced-colorectal-cancer
#7
Dong-Mei Wu, Yong-Jian Wang, Shao-Hua Fan, Juan Zhuang, Zi-Feng Zhang, Qun Shan, Xin-Rui Han, Xin Wen, Meng-Qiu Li, Bin Hu, Chun-Hui Sun, Ya-Xing Bao, Hai-Juan Xiao, Lin Yang, Jun Lu, Yuan-Lin Zheng
This network meta-analysis compared the short-term and long-term efficacies of first-line chemotherapy regimens in patients with advanced colorectal cancer (CRC). The 10 regimens included folinic acid + 5-fluorouracil + oxaliplatin (FOLFOX), folinic acid + 5-fluorouracil + irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate (FFT), folinic acid + 5-fluorouracil (FF), irinotecan + oxaliplatin (IROX), raltitrexed + oxaliplatin (TOMOX), folinic acid + tegafur-uracil (FTU), raltitrexed, and capecitabine...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29233603/individual-susceptibility-analysis-using-patient-derived-slice-cultures-of-colorectal-carcinoma
#8
Rasmus Sönnichsen, Laura Hennig, Vera Blaschke, Karsten Winter, Justus Körfer, Susann Hähnel, Astrid Monecke, Christian Wittekind, Boris Jansen-Winkeln, René Thieme, Ines Gockel, Kerstin Grosser, Arved Weimann, Christoph Kubick, Volker Wiechmann, Achim Aigner, Ingo Bechmann, Florian Lordick, Sonja Kallendrusch
BACKGROUND: Nonresponse to chemotherapy in colorectal carcinoma (CRC) is still a clinical problem. For most established treatment regimens, no predictive biomarkers are available. Patient-derived tumor slice culture may be a promising ex vivo technology to assess the drug susceptibility in individual tumors. METHODS: Patient-derived slice cultures of CRC specimens were prepared according to a standardized protocol and treated with different concentrations of 5-fluorouracil (5-FU) and an adapted FOLFOX regimen (5-FU and oxaliplatin) to investigate histologic response...
November 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29219177/current-status-and-future-prospective-of-curcumin-as-a-potential-therapeutic-agent-in-the-treatment-of-colorectal-cancer
#9
REVIEW
Mohammad Jalili-Nik, Arash Soltani, Soussan Moussavi, Majid Ghayour-Mobarhan, Gordon A Ferns, Seyed Mahdi Hassanian, Amir Avan
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide. Hence there is a need to identify new therapeutic agents that improve the current repertoire of chemotherapeutic drugs. The antitumor activity of curcumin has been reported for several tumors, including CRC. A recent phase I trial showed that curcumin is safe and tolerable adjunct to FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in patient-derived colorectal liver metastases at doses up to 2 grams daily...
December 8, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29218616/noninvasive-assessment-of-hepatic-sinusoidal-obstructive-syndrome-using-acoustic-radiation-force-impulse-elastography-imaging-a-proof-of-concept-study-in-rat-models
#10
So Hyun Park, Seung Soo Lee, Ji-Youn Sung, Kiyong Na, Hyoung Jung Kim, So Yeon Kim, Beom Jin Park, Jae Ho Byun
OBJECTIVES: To determine the feasibility of acoustic radiation force impulse (ARFI) elastography in the evaluation of hepatic sinusoidal obstruction syndrome (SOS) in rat models. METHODS: Rat SOS models of various severities were created by monocrotaline gavage (n = 40) or by intraperitoneal injection of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) (n = 16). Liver shear-wave velocity (SWV) was measured using ARFI elastography. Liver samples were analysed for the SOS score, steatosis, lobular inflammation and fibrosis...
December 7, 2017: European Radiology
https://www.readbyqxmd.com/read/29211295/phase-2-study-of-treatment-selection-based-on-tumor-thymidylate-synthase-expression-in-previously-untreated-patients-with-metastatic-colorectal-cancer-a-trial-of-the-ecog-acrin-cancer-research-group-e4203
#11
Neal J Meropol, Yang Feng, Jean L Grem, Mary F Mulcahy, Paul J Catalano, John S Kauh, Michael J Hall, Joel N Saltzman, Thomas J George, Jeffrey Zangmeister, Elena G Chiorean, Puneet S Cheema, Peter J O'Dwyer, Al B Benson
BACKGROUND: The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors. METHODS: TS protein expression was determined in mCRC tissue...
December 6, 2017: Cancer
https://www.readbyqxmd.com/read/29187492/folfox-as-first-line-therapy-for-gastric-cancer-with-severe-peritoneal-metastasis
#12
Toshiki Masuishi, Shigenori Kadowaki, Mayumi Kondo, Azusa Komori, Keiji Sugiyama, Seiichiro Mitani, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Hideyuki Mishima, Kei Muro
BACKGROUND/AIM: Severe peritoneal metastasis (PM) from advanced gastric cancer (AGC) causes massive ascites and inadequate oral intake. Because patients with severe PM are often not included in clinical trials, little is known regarding the efficacy and safety of oxaliplatin with l-leucovorin and bolus/continuous infusion of 5-fluorouracil (FOLFOX) for them. PATIENTS AND METHODS: We retrospectively studied AGC patients with massive ascites and/or inadequate oral intake due to severe PM treated with FOLFOX as the first-line treatment...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29184856/optimal-therapy-for-patients-with-hepatocellular-carcinoma-and-resistance-or-intolerance-to-sorafenib-challenges-and-solutions
#13
REVIEW
Emily M Ray, Hanna K Sanoff
The only US Food and Drug Administration (FDA)-approved first-line systemic therapy for hepatocellular carcinoma (HCC) is sorafenib; however, resistance or intolerance to sorafenib is unfortunately common. In this review, we briefly describe systemic therapies that can be considered for patients with HCC who show resistance or intolerance to sorafenib. For all patients with HCC who need systemic therapy, we strongly advocate for participation in clinical trials. Cytotoxic chemotherapy plays a minor role in the treatment of advanced HCC, with some data supporting the use of FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) and GEMOX (gemcitabine-oxaliplatin)...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29184698/case-report-primary-acinar-cell-carcinoma-of-the-liver-treated-with-multimodality-therapy
#14
Emmet J Jordan, Olca Basturk, Jinru Shia, David S Klimstra, William Alago, Michael I D'Angelica, Ghassan K Abou-Alfa, Eileen M O'Reilly, Maeve A Lowery
We describe a case of primary acinar cell carcinoma (ACC) originating in the liver in a 54-year-old female, diagnosed following persistent abnormal elevated liver function. Imaging revealed two masses, one dominant lesion in the right hepatic lobe and another in segment IVA. A right hepatectomy was performed to remove the larger lesion, while the mass in segment IVA was unresectable due to its proximity to the left hepatic vein. Immunohistochemical staining showed positivity for trypsin and chymotrypsin. Postoperatively the patient underwent hepatic arterial embolization of the other unresectable lesion followed by FOLFOX chemotherapy...
October 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29177097/exploration-of-time-points-and-cut-off-values-for-early-tumour-shrinkage-to-predict-survival-outcomes-of-patients-with-metastatic-colorectal-cancer-treated-with-first-line-chemotherapy-using-a-biexponential-model-for-change-in-tumour-size
#15
Kentaro Sakamaki, Yosuke Kito, Kentaro Yamazaki, Naoki Izawa, Takashi Tsuda, Satoshi Morita, Narikazu Boku
Background: Several studies reported that early tumour shrinkage (ETS) was associated with overall survival in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. However, appropriate time point and cut-off value for ETS remain unclear because these varied in previous studies. Patients and methods: We investigated patients with mCRC who received FOLFOX or FOLFIRI with/without molecular-targeted agents as first-line treatment between 2005 and 2014...
2017: ESMO Open
https://www.readbyqxmd.com/read/29167892/association-of-prognostic-value-of-primary-tumor-location-in-stage-iii-colon-cancer-with-ras-and-braf-mutational-status
#16
Julien Taieb, Hampig Raphael Kourie, Jean-François Emile, Karine Le Malicot, Ralyath Balogoun, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Claire Mulot, Olivier Bouché, Thomas Aparicio, Pierre Michel, Josef Thaler, John Bridgewater, Eric Van Cutsem, Géraldine Perkins, Come Lepage, Ramon Salazar, Pierre Laurent-Puig
Importance: We know of no data on the prognostic value of primary tumor location (PTL) according to BRAF, RAS, and microsatellite instability (MSI) status in patients who have undergone resection for colon cancer (CC) and have been treated with current standard adjuvant chemotherapy. Objective: To determine the prognostic and predictive value of PTL according to BRAF, RAS, and MSI status in patients with stage III CC receiving adjuvant treatment with FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) with or without cetuximab...
November 22, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29163699/comparison-of-adjuvant-folfox4-chemotherapy-and-oral-ufur-lv-following-adjuvant-folfox4-chemotherapy-in-patients-with-stage-iii-colon-cancer-subsequent-to-radical-resection
#17
Ming-Yii Huang, Chun-Ming Huang, Hsiang-Lin Tsai, Ching-Wen Huang, Hui-Min Hsieh, Yung-Sung Yeh, Jeng-Yih Wu, Wen-Ming Wang, Jaw-Yuan Wang
The present study aimed to demonstrate the potential advantage of oral uracil-tegafur (UFUR)/leucovorin (LV) as the subsequent therapy in patients with stage III colon cancer following adjuvant LV, 5-fluorouracil and oxaliplatin (FOLFOX4) chemotherapy. Of a total 143 patients, 62 patients received only FOLFOX adjuvant chemotherapy (FOLFOX4 biweekly × 12 cycles for 6 months), and 81 patients received FOLFOXU adjuvant treatment (which consisted of FOLFOX4 biweekly × 12 cycles for 6 months followed by oral UFUR/LV for an additional 6 months)...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29159476/the-impact-of-skeletal-muscle-on-the-pharmacokinetics-and-toxicity-of-5-fluorouracil-in-colorectal-cancer
#18
Grant R Williams, Allison M Deal, Shlomit Strulov Shachar, Christine M Walko, Jai N Patel, Bert O'Neil, Howard L McLeod, Marc S Weinberg, Seul Ki Choi, Hyman B Muss, Hanna K Sanoff
PURPOSE: Great heterogeneity exists in the ability of adults with cancer to tolerate chemotherapy. Variability in body composition may affect rates of metabolism of cytotoxic agents and contribute to the variable chemotherapy toxicity observed. The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer. METHODS: We performed a secondary analysis of a completed multicenter trial that investigated PK-guided 5FU dosing in patients receiving mFOLFOX6 +/- bevacizumab for colorectal cancer...
November 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29155512/efficacy-and-safety-of-cetuximab-plus-folfox-in-second-line-and-third-line-therapy-in-metastatic-colorectal-cancer
#19
Ersin Ozaslan, Ulas Serkan Topaloglu, Mevlude Inanc, Umut Gokmen Erdem, Hacer Demir, Erkan Arpaci, Mehmet Metin Seker, Mustafa Karaagac, Melih Kiziltepe, Baki Eker, Metin Ozkan
PURPOSE: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. METHODS: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were alsï given irinïtecan and/ïr ïxaliplatin cïmbined with fluorïpyrimidine±bevacizumab. Tumor respïnse and survival were evaluated using RECIST and Kaplan-Meier methïd respectively...
July 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29153096/correlations-between-microsatellite-instability-ercc1-xrcc1-polymorphism-and-clinical-characteristics-and-folfox-adjuvant-chemotherapy-effect-of-colorectal-cancer-patients
#20
Liping Zhang, Jiangman Zhao, Bin Yu, Xinjiang Song, Guogang Sun, Lijiang Han, Lu Wang, Shu Dong
Patients with MSI colorectal tumor have good prognosis and cannot benefit from 5-fluorouracil (5-Fu)-based chemotherapy reported by previous studies. While, single nucleotide polymorphisms (SNP) of ERCC1 and XRCC1 have be proved to influence clinical outcome of colorectal cancer patients treated with oxaliplatin-based chemotherapy. We aim to study the correlation between molecular status and clinical- pathological features, and their effect on CRC patients' clinical outcome treated with mFOLFOX6 adjuvant chemotherapy...
December 2017: Cancer Genetics
keyword
keyword
2273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"